Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Finished Goods (2023 - 2024)

Telix Pharmaceuticals has reported Finished Goods over the past 2 years, most recently at $9.2 million for Q4 2024.

  • Quarterly Finished Goods rose 286.24% to $9.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Dec 2024, up 286.24% year-over-year, with the annual reading at $9.2 million for FY2024, 286.24% up from the prior year.
  • Finished Goods was $9.2 million for Q4 2024 at Telix Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Over five years, Finished Goods peaked at $9.2 million in Q4 2024 and troughed at $2.4 million in Q4 2023.